Promopharm SA
CCSEMA:PRO1,480.00
MAD
+82.00
(+5.87%)
Promopharm SA
CSEMA:PRO
(Casablanca Stock Exchange)
Recent
price
1,480.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Promopharm SA is a Morocco-based pharmaceutical manufacturing, marketing, and distribution company that operates as a subsidiary of Hikma Pharmaceuticals PLC. Founded in 1949 and headquartered in Casablanca (Had Soualem), Morocco, the company develops, manufactures, and distributes branded generic pharmaceuticals, licensed originator medications, over-the-counter (OTC) treatments, medical devices, and parapharmaceutical products. Promopharm SA operates primarily in the healthcare and pharmaceutical sector, serving retail pharmacies, private clinics, public and private hospital networks, and wholesale distributors across Morocco and export markets throughout Sub-Saharan Africa and the Middle East and North Africa (MENA) region. The company's core product portfolio encompasses a broad spectrum of therapeutic categories, including: central nervous system (CNS) and psychiatric treatments; cardiovascular, antihypertensive, and metabolic medications; anti-infectives, systemic antibiotics, and antiviral therapies; respiratory and anti-allergic formulations, including expectorants, bronchodilators, and antihistamines; gastrointestinal and digestive health products, such as proton-pump inhibitors and antacids; musculoskeletal and pain management treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and antipyretics; dermatological creams, gels, and topical formulations; ophthalmic and otic preparations; and dietary supplements, multivitamins, and pediatric formulations. The company manufactures diverse pharmaceutical dosage forms, including: oral solids such as tablets, capsules, and effervescent granules; oral liquids such as syrups, suspensions, and drops; semi-solids such as ointments, creams, and suppositories; and sterile injectables, accompanied by specialized packaging and regulatory affairs services. In addition to proprietary branded generics, Promopharm SA provides contract manufacturing, secondary packaging, and licensing partnerships for multinational pharmaceutical companies. In recent strategic and operational developments, Promopharm SA has expanded its industrial footprint at its Had Soualem manufacturing facility through investments in automated high-speed production lines, modernized sterile preparation suites, and upgraded quality control laboratories aligned with international Good Manufacturing Practice (GMP) standards. To support Morocco's national health sovereignty initiative and generalized compulsory health insurance (AMO) coverage, the company has broadened its commercial offering with the launch of new generic molecules targeting chronic pathologies, oncology supportive care, and metabolic disorders. Furthermore, Promopharm SA has deepened operational synergies with parent company Hikma Pharmaceuticals PLC to scale export distribution across Francophone West Africa, entered into new co-marketing and localized manufacturing alliances with international drug developers, and implemented industrial sustainability initiatives, including the integration of on-site solar power generation and energy-efficient utility systems across its manufacturing site.